Streetbeat News

Analyst Ratings

SHPW

Needham analyst James Ricchiuti has maintained a 'Buy' rating on Shapeways Holdings (NASDAQ:SHPW) but lowered the price target from $8 to $4.5.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:45 am

ACLX

HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Arcellx (NASDAQ:ACLX) and raises the price target from $49 to $50.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:43 am

ALPN

HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Alpine Immune Sciences (NASDAQ:ALPN) and raises the price target from $11 to $17.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:41 am

RNAZ

HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on TransCode Therapeutics (NASDAQ:RNAZ) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:40 am

CAPR

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Capricor Therapeutics (NASDAQ:CAPR) and maintained an $18 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:39 am

MBIO

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Mustang Bio (NASDAQ:MBIO) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:35 am

HRTX

Needham analyst Serge Belanger has reiterated a 'Buy' rating on Heron Therapeutics (NASDAQ:HRTX) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:33 am

ROIV

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Roivant Sciences (NASDAQ:ROIV) and maintained a price target of $18.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:31 am

DH

Needham analyst Ryan MacDonald has reiterated a 'Buy' rating on Definitive Healthcare (NASDAQ:DH) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:30 am

EMX

HC Wainwright & Co. analyst Heiko Ihle has reiterated a 'Buy' rating on EMX Royalty (AMEX:EMX) and maintained a price target of $4.75.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:29 am